NICE ‘yes’ for chronic myeloid leukaemia pill
For patients this could mean more are able to achieve a normal life expectancy, without compromising on their quality of life.
Bristol-Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending the use of Sprycel (dasatinib) for the treatment of eligible adults with the blood cancer, chronic myeloid leukaemia (CML). This guidance applies to both those who are newly diagnosed and those resistant or intolerant to previous treatment. The positive NICE decision will allow access to an effective treatment option shown to provide rapid and durable response against this cancer. For patients this could mean more are able to achieve a normal life expectancy, without compromising on their quality of life.
“Today’s decision from NICE is an important step forward in the treatment of CML,” said Doctor Jenny Byrne, Haematologist at Nottingham City Hospital. “The chronic nature of this disease means that treatment needs to be taken continuously and long-term; dasatinib is a treatment that could potentially enable many patients to achieve the goal of normal life-expectancy and to live as normal a life as possible.”
“The decision by NICE to recommend dasatinib is extremely good news for patients diagnosed with CML, a life-threatening blood cancer,” said Sandy Craine, Founder of The CML Support Group. “For people fighting this disease, timely access to potentially lifesaving targeted therapies such as dasatinib will very likely enable them to gain control over their disease and live out their normal lifespan. Access to targeted therapies such as dasatinib not only has the potential to extend their life expectancy but also represents a cost effective use of NHS resource. This is a progressive and forward thinking decision by NICE and will be welcomed by patients and clinicians alike throughout England.”
Dasatinib is licensed for first- and second-line CML and has long term clinical trial data in both these settings. In a Phase III study of newly diagnosed patients, a significantly higher proportion in the dasatinib vs. imatinib (a standard of care) group achieved the primary outcome of a confirmed complete cytogenetic response (cCCyR) by 12 months: 77% versus 66% patients respectively. Data on dasatinib in patients who had developed resistance or intolerance to previous treatment are based around Phase III and Phase II studies. In the Phase III studies, in patients with chronic, accelerated or blast phase CML, dasatinib produced haematological and cytogenetic responses.
“We are extremely pleased that NICE has recognised the significant benefits that dasatinib can offer people fighting chronic myeloid leukaemia,” said Benjamin Hickey, General Manager, BMS UK & Ireland. “Patients will now have access to an important treatment option that, in many patients, can improve their quality of life, while effectively managing the disease. We remain focused on our goal of changing the way people live with cancer and this is another vital milestone in that journey.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance